Why the study?
What are the risks of radioiodine treatment in patients with Graves' disease?
What are the risks of radioiodine treatment in patients with Graves' disease?
Radioiodine (iodine-131) is considered a safe and effective treatment of choice for most patients with Graves' disease, with no significant side effects identified over 35 years of use.
Reassures clinicians on radioiodine safety for Graves' disease; leaves open need for prospective data beyond 35 years.
Concern about the side effects of radiation exposure has deterred physicians from using radioiodine treatment for Graves' disease, although the efficacy and safety of this treatment have been established in the 35 years since its introduction. In that time, no significant side effects have been discovered. We believe iodine-131 should be considered the treatment of choice in most patients with Graves' disease. This article reviews the current understanding of the risks in radioiodine treatment of Graves' disease, including the risks for teratogenicity, genetic damage, carcinogenesis, and cellular dysfunction.
No takes yet. Share an insight, caveat, or question.
Gordon D. Graham (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: